Quest Diagnostics CEO Sells $2.43M in Common Stock Under Rule 10b5-1 Plan

Executive Summary

On September 1, 2026, James E. Davis, CEO, President, and Director of Quest Diagnostics Inc ($DGX), executed a planned sale of 10,000 shares of common stock at a price of $242.72 per share, generating gross proceeds of approximately $2.43 million.

Transaction Breakdown

• Security: Common Stock
• Transaction Type: Open Market Sale (Code: S)
• Volume: 10,000 shares
• Execution Price: $242.72 per share
• Total Consideration: $2,427,200.00
• Ownership Post-Transaction: 122,423 shares directly owned
• Pre-Arranged Plan: Yes, executed pursuant to a pre-established Rule 10b5-1 sales plan.

Analysis & Significance

• Trading Significance: Medium. As CEO and Director, sales by top leadership warrant market attention; however, the sale represents ~7.55% of Davis's direct holdings prior to the transaction (132,423 shares total), leaving him with a substantial direct stake of 122,423 shares.
• Rule 10b5-1 Context: The transaction was pre-scheduled under a Rule 10b5-1 plan, mitigating concerns regarding opportunistic timing or non-public material information.